中图分类号 R979.1；R730.5 文献标志码 A 文章编号 1001-0408(2025)11-1289-12

    DOI 10.6039/j.issn.1001-0408.2025.11.01

    ABSTRACT OBJECTIVE To promote the rational use of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/ mammalian target of rapamycin(mTOR)inhibitors in breast cancer treatment and provide guidance for pharmacists to implement homogeneous medication therapy management. METHODS A multidisciplinary panel comprising content experts (clinical medicine，pharmacy) and methodological experts (evidence-based medicine，statistics，medical ethics) was assembled using the Nominal Group Technique. A draft consensus was developed through systematic literature retrieval， analysis， and synthesis. External reviewers evaluated the draft via questionnaire-based feedback and revisions were incorporated to finalize the consensus. RESULTS This consensus framework focuses on the medication therapy management process of PI3K/Akt/mTOR inhibitors with information collection，treatment regimen evaluation and pharmaceutical intervention structure modules. Seven critical issues and eight evidence-based recommendations were addressed ......